Science: Our approach
De-risked drug development
Missing the target is the biggest risk for targeted drug delivery.
Many promising Antibody-Drug Conjugates failed because they failed to target. What is worse, these failures typically emerged at the later stages of clinical development. Such late-stage failures are a huge waste of time and money.
Targeting can be confirmed by means of in-life molecular imaging, but this demands high-level expertise and infrastructure.
At LinXis, molecular imaging is our bread and butter - and we apply it from the earliest stages of drug development onward.
Using
molecular imaging we have extensively validated the targeting ability
of our lead Fibrobody® in preclinical models - and we are all set to validate it in patients.
The possibilities are endless
We have validated our lead Fibrobody® in numerous types of Fibrosis, demonstrating it to be a truly pan-fibrotic drug delivery vehicle.
Fibrobodies® can be functionalized with virtually all types of antifibrotic drugs and agents. Through our molecular imaging-guided development drug strategy we can quickly and efficiently come to effective diagnostic and therapeutic conjugates.
The impact of Fibrobodies®
Small enough to reach myofibroblasts, Fibrobodies® are species-cross-reactive
Fibrobodies® can be produced quickly and in large quantities
Fibrobodies® are a perfect delivery vehicle that can be equipped with any cargo
Extensively validated targeting ability